Stock OTLC ONCOTELIC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Delayed OTC Markets
Other stock markets
 11:49:04 2024-05-01 am EDT 		5-day change 1st Jan Change
0.0388 USD -2.88% Intraday chart for Oncotelic Therapeutics, Inc. +7.78% +1.31%
Apr. 12 Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 25 Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AQ
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Oncotelic Therapeutics, Inc. - Linkage of Cancer and Lupus in Gliomas Patients
AQ
Linkage of Cancer and Lupus in Gliomas Patients
AQ
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients
CI
Invitation to Participate in STOP-PC Clinical Trial
AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)
AQ
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)
AQ
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
AQ
Oncotelic Therapeutics Announces CEO to Discuss Proprietary AI Technology at Ibero-American Chatbot Summit
AQ
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
AQ
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000
MT
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
AQ
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Oncotelic Therapeutics, Inc. announces tranche update
CI
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023
AQ
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023
AQ
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
AQ
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OTLC Stock
  4. News Oncotelic Therapeutics, Inc.